Four patients had mutations that were not found in available archival tumour tissue (archival tissue available for 26 patients); 3 were PIK3CA mutations, and 1 had multiple mutations in BRAF, KRAS and NRAS. These could reflect tumour heterogeneity, genetic evolution of the tumour with treatment, or both. This evidence concerns the gene BRAF and neoplasm.